Summary unavailable.

Questions

Question 1

What is the primary use of NSAIDs, aspirin, and other salicylates in the management of rheumatoid arthritis?

View answer and explanation
Question 2

Why are corticosteroids primarily reserved for more advanced swelling and discomfort in the treatment of rheumatoid arthritis?

View answer and explanation
Question 3

Which class of antirheumatic drugs is specifically designed to slow the progression of rheumatoid arthritis and delay joint destruction?

View answer and explanation
Question 4

What is a significant limitation shared by both NSAIDs and corticosteroids in the long-term management of rheumatoid arthritis?

View answer and explanation
Question 5

For which type of rheumatoid arthritis cases are Disease-modifying antirheumatic drugs (DMARDs) typically reserved?

View answer and explanation
Question 6

What is the primary reason cited in the text for reserving Disease-modifying antirheumatic drugs (DMARDs) for severe cases of rheumatoid arthritis?

View answer and explanation
Question 7

How long might a patient need to be on therapy with Disease-modifying antirheumatic drugs (DMARDs) before a benefit is noted?

View answer and explanation
Question 8

What is the general mechanism of action for most Disease-modifying antirheumatic drugs (DMARDs)?

View answer and explanation
Question 9

A patient reports an allergy to aspirin. Which other class of antirheumatic medication should this patient not receive?

View answer and explanation
Question 10

In which patient population are corticosteroids contraindicated for the treatment of rheumatoid arthritis?

View answer and explanation
Question 11

What specific precaution should be taken when prescribing NSAIDs and corticosteroids to patients?

View answer and explanation
Question 12

Due to their immunosuppressive properties, Disease-modifying antirheumatic drugs (DMARDs) should be avoided in patients with which of the following conditions?

View answer and explanation
Question 13

What is a potential interaction when NSAIDs are used concurrently with diuretics and other antihypertensives?

View answer and explanation
Question 14

Concurrent use of corticosteroids with certain other medications may lead to what potential adverse effect related to digoxin?

View answer and explanation
Question 15

What is the primary risk of using Disease-modifying antirheumatic drugs (DMARDs) concurrently with other immunosuppressants?

View answer and explanation
Question 16

Which type of vaccination should not be administered concurrently with Disease-modifying antirheumatic drugs (DMARDs)?

View answer and explanation
Question 17

According to the nursing implications, how frequently should a patient undergoing antirheumatic therapy be assessed for pain, swelling, and range of motion?

View answer and explanation
Question 18

What is the primary reason that most antirheumatic agents require regular administration?

View answer and explanation
Question 19

What is the primary desired outcome of antirheumatic therapy as listed in the Evaluation section?

View answer and explanation
Question 20

Corticosteroids are particularly useful in controlling what aspect of rheumatoid arthritis?

View answer and explanation
Question 21

What therapeutic property is shared by both NSAIDs and corticosteroids in the treatment of rheumatoid arthritis?

View answer and explanation
Question 22

In severe cases of rheumatoid arthritis, what is the main therapeutic goal of using antirheumatics?

View answer and explanation
Question 23

What action may be required if a patient on DMARDs experiences serious and frequent adverse reactions?

View answer and explanation
Question 24

A patient with which pre-existing condition should use corticosteroids with caution?

View answer and explanation
Question 25

Which of the following is listed in the text as a potential nursing diagnosis for a patient receiving antirheumatic therapy?

View answer and explanation
Question 26

In which patient population should DMARDs be avoided due to the significant risk posed by their immunosuppressive properties?

View answer and explanation
Question 27

What instruction should be given to a patient regarding the initial effectiveness of their antirheumatic therapy?

View answer and explanation
Question 28

Which class of antirheumatic drugs is NOT noted for preventing disease progression or joint destruction?

View answer and explanation
Question 29

What is the primary reason corticosteroids are used to manage advanced swelling and discomfort in rheumatoid arthritis, despite their side effects?

View answer and explanation
Question 30

What is a defining characteristic of Disease-modifying antirheumatic drugs (DMARDs) regarding their therapeutic onset?

View answer and explanation
Question 31

If a patient is receiving therapy with a Disease-modifying antirheumatic drug (DMARD), which of the following should be avoided?

View answer and explanation
Question 32

The use of corticosteroids may increase the risk of toxicity from which cardiac medication due to the potential for augmenting hypokalemia?

View answer and explanation
Question 33

A patient taking a diuretic for hypertension begins therapy with an NSAID for rheumatoid arthritis. What potential interaction should the nurse be aware of?

View answer and explanation
Question 34

What is a primary side effect concern that contributes to corticosteroids being reserved for more advanced cases of rheumatoid arthritis?

View answer and explanation
Question 35

The management of rheumatoid arthritis symptoms such as pain and swelling is a primary use for which class of medications?

View answer and explanation
Question 36

The text states that serious and frequent adverse reactions to DMARDs might occur despite what circumstance?

View answer and explanation
Question 37

The idea that the autoimmune response is responsible for joint destruction is the basis for the mechanism of action of which drug class?

View answer and explanation
Question 38

What is a general contraindication listed for antirheumatic agents?

View answer and explanation
Question 39

In addition to patients with active infections and underlying malignancy, in which other group should DMARDs be avoided due to the risks of immunosuppression?

View answer and explanation
Question 40

The text lists the potential nursing diagnosis 'Chronic pain' under what specific category?

View answer and explanation
Question 41

What is the primary focus of the recommended monthly assessment for patients on antirheumatic therapy?

View answer and explanation
Question 42

What is the primary consequence of using DMARDs with other immunosuppressants?

View answer and explanation
Question 43

Which drug class for rheumatoid arthritis is specifically noted for its toxicity, necessitating its reservation for severe cases?

View answer and explanation
Question 44

Which of the following is an intended therapeutic outcome of using antirheumatic drugs for symptom management?

View answer and explanation
Question 45

A patient receiving corticosteroids for rheumatoid arthritis should be monitored for interactions that might lead to which electrolyte imbalance?

View answer and explanation
Question 46

A patient with an active, untreated infection should not be treated with which antirheumatic agent?

View answer and explanation
Question 47

Which statement most accurately describes the role of Disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis management?

View answer and explanation
Question 48

A key teaching point for a patient starting on a DMARD is that the therapy...

View answer and explanation
Question 49

Which of the following is NOT a primary goal of antirheumatic therapy as described in the text?

View answer and explanation
Question 50

Concurrent use of which two drug classes is contraindicated in a patient with a known aspirin allergy?

View answer and explanation

Other chapters

HOW TO USE DAVIS'S DRUG GUIDE FOR NURSESEVIDENCE-BASED PRACTICE AND PHARMACOTHERAPEUTICS: Implications for NursesPHARMACOGENOMICSMEDICATION ERRORS: Improving Practices and Patient SafetyDETECTING AND MANAGING ADVERSE DRUG REACTIONSOVERVIEW OF RISK EVALUATION AND MITIGATION SYSTEMS (REMS)SPECIAL DOSING CONSIDERATIONSTHE CYTOCHROME P450 SYSTEMEDUCATING PATIENTS ABOUT SAFE MEDICATION USEAnti-Alzheimer's agentsAntianemicsAntianginalsAntianxiety agentsAntiarrhythmicsAntiasthmaticsAnticholinergicsAnticoagulantsAnticonvulsantsAntidepressantsAntidiabeticsAntidiarrhealsAntiemeticsAntifungalsAntihistaminesAntihypertensivesAnti-infectivesAntineoplasticsAntiparkinson agentsAntiplatelet agentsAntipsychoticsAntipyreticsAntiulcer agentsAntiviralsBeta blockersBone resorption inhibitorsBronchodilatorsCalcium channel blockersCentral nervous system stimulantsCorticosteroidsDiureticsHormonesImmunosuppressantsLaxativesLipid lowering agentsMinerals/electrolytes/pH modifiersNonopioid analgesicsNonsteroidal anti-inflammatory agentsOpioid analgesicsSedative/hypnoticsSkeletal muscle relaxantsThrombolyticsVaccines/immunizing agentsVitaminsDRUGS APPROVED IN CANADANATURAL/HERBAL PRODUCTSMEDICATION SAFETY TOOLSAppendix A. Recent Drug ApprovalsAppendix E. Administering Medications to ChildrenAppendix G. Pediatric Dosage CalculationsAppendix I. Controlled Substance SchedulesAppendix L. Insulins and Insulin TherapyAppendix M. Canadian and U.S. Pharmaceutical PracticesAppendix N. Routine Pediatric and Adult Immunizations